Document is current
Any future updates will be listed below
-
Authors
Yotsumoto, Daisuke
Sagara, Yasuaki https://orcid.org/0000-0001-5705-1739
Kumamaru, Hiraku
Niikura, Naoki
Miyata, Hiroaki
Kanbayashi, Chizuko
Tsuda, Hitoshi
Yamamoto, Yutaka
Aogi, Kenjiro
Kubo, Makoto
Tamura, Kenji
Hayashi, Naoki
Miyashita, Minoru
Kadoya, Takayuki
Saji, Shigehira
Toi, Masakazu
Imoto, Shigeru
Jinno, Hiromitsu
-
Funding
Funding for this research was provided by:
the National Cancer Center Research and Development fund (26-A-4)
the Japan Agency for Medical Research and Development, AMED (19ck0106307h0002)
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 10 October 2021
First Online: 19 October 2021
Declarations
:
: Hiraku Kumamaru and Hiroaki Miyata are affiliated with the department of Healthcare Quality Assessment at the university of Tokyo. The department is a social collaboration department supported by National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Naoki Niikura has received grants and personal fees from Chugai, Pfizer, Eisai, Daiichi Sankyo, MSD, grants from Novartis, Eisai, AstraZeneka, Kyowa Hakko Kirin, Nippon Mediphysics, Takeda, Taiho, Nippon Kayaku, Eli Lilly. Hitoshi Tsuda has received grants from Taiho, Goryo Chemical, personal fees and other from Chugai, other from Takeda, Eli Lilly. Yutaka Yamamoto has received grants and personal fees from Chugai, Kyowa Hakko Kirin, Eli Lilly, Nihon Kayaku, personal fees from Taiho, Daiichi Sankyo, AstraZeneca, Novartis, Eisai, Takeda, Pfizer. Naoki Hayashi has received personal fees from Chugai, Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Genomic Health inc. Minoru Miyashita has received personal fees from Chugai, Eli Lilly, Eisai, AstraZeneca, Pfizer, Taiho, Daiichi Sankyo, non-financial support from Kyowa Hakko Kirin. Kenjiro Aogi has received personal fees as honoraria from Chugai, Eisai, AstraZeneca, Taiho, Novartis, Daiichi Sankyo, Mochida, Ono, Eli Lilly, and his institution received research funds from Chuai, Eisai, Takeda. Shigehira Saji has received grants and personal fees from Chugai, Kyowa Hakko Kirin, Eli Lilly, AstraZeneca, Novartis, Eisai, Takeda, personal fees from Pfizer, MSD, Daiichi Sankyo, grants from Taiho. Masakazu Toi has received grants and personal fees from Chugai, Takeda, Pfizer, Kyowa Hakko Kirin, C & C Res Lab, Taiho, Eisai, Daiichi Sankyo, AstraZeneca, grants from JBCRG association, Astellas, personal fees from Eli Lilly, MSD, Genomic Health, Novartis, Konica Minolta, outside the submitted work; and Board of directors; JBCRG association, Organization for Oncology and Translational Research, Kyoto Breast cancer Research Network. The other authors have no conflict of interest.
